Home administration of bortezomib: making a difference to myeloma patients' lives.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Affiliation
St Josephs Ward, Galway University Hospital, Newcastle Road, Galway, Ireland. onc.haematology@hse.ieIssue Date
2010-04MeSH
Antineoplastic AgentsBoronic Acids
Female
Home Care Services
Humans
Injections, Intravenous
Ireland
Male
Multiple Myeloma
Pilot Projects
Pyrazines
Treatment Outcome
Metadata
Show full item recordCitation
Home administration of bortezomib: making a difference to myeloma patients' lives. 2010, 14 (2):134-6 Eur J Oncol NursJournal
European journal of oncology nursing : the official journal of European Oncology Nursing SocietyDOI
10.1016/j.ejon.2009.09.003PubMed ID
19818684Language
enISSN
1532-2122Ethical Approval
N/Aae974a485f413a2113503eed53cd6c53
10.1016/j.ejon.2009.09.003
Scopus Count
Collections
Related articles
- Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
- Authors: Terpos E
- Issue date: 2008 Nov
- The efficacy and safety of bortezomib (velcade) in the treatment of relapsed multiple mye.
- Authors: Warzocha K, Kraj M, Pogłód R, Sokołowska U
- Issue date: 2006 Sep-Oct
- Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
- Authors: Ozkurt ZN, Sucak GT, Aki SZ, Yağci M, Erdem O
- Issue date: 2009
- Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
- Authors: Laura R, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Bladé J, Montserrat E
- Issue date: 2006 May
- [Velcade for multiple myeloma. A new method of administration].
- Issue date: 2012 Sep-Oct